Elizabeth M Burton

8PUBLICATIONS
155CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

|Mar 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

Li Zhou, Milton Jose Barros E Silva, Edward Hsiao

|Apr 08, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.

Isabella C Glitza, Yongwoo David Seo, Christine N Spencer

|Feb 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.

Christina L Roland, Elise F Nassif Haddad, Emily Z Keung

|May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

Claus Garbe, Reinhard Dummer, Teresa Amaral

|Sep 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.

Andrew W Hahn, Ashley V Menk, Dayana B Rivadeneira

Pageof 2

Frequent Collaborators

6 joint publications

Hussein A Tawbi

4 joint publications

Alexander Lazar

3 joint publications

Christine N Spencer

3 joint publications

Jennifer L McQuade